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1) Ferreira, JJ et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.
European Journal of Neurology. 2013; 20: 5-15 The analysis suggests that adding a PKG to a PD patient's therapy management may significantly improve, and subsequently sustain, patient PD scores over time. This is important as, due to the natural progression of PD, one would expect PKG symptom scores to deteriorate over time. Other potential PKG benefits were not part of this analysis. The PKG represents additional, complementary value in PD management with respect to classical patient-reported, questionnaire-based instruments, which do not deliver objective data.
There was a statistically significant improvement on average in the scores from the second PKG in those patients whose scores on the first PKG were considered "uncontrolled" (BKS high, DKS high, FDS low or high). 43% of patients whose FDS <8 and 34% of patients whose FDS >9 (i.e. uncontrolled at baseline) had scores considered "controlled" in their second PKG (Fig. 1 ). There is a statistically significant improvement in the sub-groups of high and low FDS of about 1 unit which is deemed a meaningful effect 4 .
The study would be strengthened with a control group as it would provide support that the PKG was causal in influencing clinical decision making. BKS, DKS and FDS are scores quantifying the key movement symptoms of PD and are the target of currently available PD therapies. This retrospective analysis aims to assess whether there was improvement in the PD symptom scores -specifically the Bradykinesia Score (BKS), Dyskinesia Score (DKS) and Fluctuation Dyskinesia Score (FDS) -provided by the PKG recordings from patients who received consecutive PKG analyses in routine care.
PD patients within the central repository who had more than 2 PKG records within a 6-month time frame were eligible for analysis. A total of 592 reports were included and split into "controlled" and "uncontrolled" at baseline (first PKG), based on pre-defined cut-off scores for BKS (median >23) or DKS (median >5); for FDS, a normal range was defined (8-9), above and below which patients were considered "uncontrolled". The Mann-Whitney U test was used for analysis.
In assessing bradykinesia, patients whose baseline BKS >23 were included, and there was a statistically and clinically significant reduction in the second PKG scores ( Fig. 2 and Table 1 ). All improved scores were sustained or somewhat augmented on average in those patients having more than 2 PKG records 5 .
69% of patients with high DKS at baseline showed some improvement, and in 33% this improvement even resulted in "controlled" scores (DKS<5.0). The reduction in DKS is statistically significant (p=0.0001) and the effect is deemed clinically meaningful (-3.6 DKS). 
Change of BKS Percentage
Switch into "controlled" range (BKS<23) 19%
Greater than 1 BKS unit improvement 18%
Greater than 1.5 BKS units improvement 17%
Greater than 2 BKS units improvement 16% 
